Posts
Est. 2026 · Pennsylvania
The List
100,000 Patients · 30 Deaths Per Day · The Managed Queue
The transplant waitlist is not a line. It is an algorithm — a ranked, scored, geographically bounded queue whose outputs are determined by policy decisions UNOS made, that embedded inequity by race and zip code, and that produced a daily death toll that was not random but predictable. The people on the list did not die waiting. They died inside the architecture.
on waitlist
historical rate
too sick to transplant
performed 2024–2025
The public image of the organ waitlist is a queue — a line of patients waiting their turn, advancing as organs become available, with the sickest and most urgent patients moving to the front. This image is not wrong in every detail. Urgency and medical need are real factors in allocation. But it misses the most important structural feature of the list: it is not a neutral system for managing scarcity. It is an architecture, and its architecture encodes values.
The waitlist is managed through a set of scoring systems — MELD for liver, KDPI and EPTS for kidney, UNOS-developed criteria for heart and lung — that translate a patient's medical condition, time waiting, location, blood type, and sensitization status into a ranked position relative to available organs. These scores determine who receives an offer when an organ becomes available. The scores are not objective. They are policy — value judgments expressed in mathematical form, developed by committees whose membership has historically reflected the transplant professional community more than the patient community.
And the scores interact with geography in a way that produces outcomes most patients on the list do not understand when they are listed: where you live determines, in large part, how long you wait — not because organs are more or less available in different places, but because UNOS's allocation policy for most of its history distributed organs within geographic boundaries that produced enormous regional disparities in waiting time.
The waiting list does not kill people. The gap between being on the list and receiving an organ kills people. That gap is not random. It is the measurable output of allocation policy — policy that a private nonprofit set, governed, and defended for 37 years.
The kidney dominance of the waitlist is the central fact of organ allocation in America. Kidney disease is a condition of scale — approximately 800,000 Americans have end-stage renal disease, many more have chronic kidney disease progressing toward it. The waitlist is predominantly a kidney crisis, and the allocation policies, discard rates, and performance failures that this series documents disproportionately affect kidney patients. The gap between the number of patients who need kidneys and the number of kidneys transplanted each year is where most of the daily death toll lives.
For most of UNOS's tenure, the allocation policy for kidneys prioritized local and regional placement over national distribution. Organs were first offered within the donor's local area, then to the region, then nationally. The policy was designed to reduce cold ischemia time — the period between organ recovery and transplant during which the organ deteriorates. Keeping organs local reduced travel time and improved outcomes, the theory ran.
The problem was that the supply of deceased donors and the density of patients on the waitlist are not evenly distributed across the country. In regions where donor rates are high and patient populations are smaller — parts of the Midwest, for example — waiting times could be measured in months. In regions where patient density is high and donor rates are lower — the Northeast and West Coast urban centers — the same patient might wait five, seven, or ten years. Not because they were less sick, not because their need was less urgent, but because of their zip code. The allocation policy converted geography into survival probability.
The geographic lottery was not invisible. It was documented in GAO reports, academic literature, and patient advocacy campaigns. UNOS defended regional priority on medical grounds — cold ischemia time, logistics, outcomes data. Critics argued that the medical rationale was used to protect local transplant center volumes and regional OPO performance metrics, not to optimize patient outcomes nationally. Both arguments had evidentiary support. The structural result — that where you lived determined how long you waited — was not disputed.
The racial disparities in organ transplant access are among the most thoroughly documented inequities in American medicine. They operate at every stage of the access funnel — from diagnosis to referral to evaluation to listing to offer acceptance to post-transplant outcomes — and they compound. A Black patient is less likely to be referred for transplant evaluation than a white patient with the same diagnosis. Less likely to be evaluated and listed. Once listed, likely to wait longer. The disadvantage is not localized to a single policy decision. It is distributed across the system's architecture.
The allocation scores that determine position on the waitlist are not neutral algorithms. They are value choices encoded in mathematics — choices about what matters, which factors to weight, which outcomes to optimize. They were developed over decades by committees whose composition reflected the transplant professional community, and they embed assumptions about what "fair" allocation looks like that are contestable.
Being on the waitlist is not the same as being in the queue for an organ. Between the point of diagnosis and the point of transplant, there is a multi-stage access funnel — each stage a point where patients can be lost, delayed, or disadvantaged. The publicly visible number — 103,000+ on the waitlist — represents only the patients who have successfully navigated through the funnel's earlier stages. The patients who were never referred, never evaluated, or never listed are invisible in the OPTN data.
Thirty patients dying per day on the transplant waitlist could, in one framing, be read as the tragic but inevitable consequence of organ scarcity — more patients need organs than die in circumstances where donation is possible, and the gap cannot be closed by any allocation system. This framing is partially true. The scarcity is genuine. Not every death on the waitlist is attributable to allocation failure.
But a significant portion is. The discard of recoverable kidneys — explored in Post IV — removes viable organs from the supply before they reach listed patients. The geographic disparity in waiting time means that patients in some regions die waiting for organs that would have been transplanted within months if those patients lived elsewhere. The pre-listing attrition documented in the access funnel means the waitlist number understates the true population of patients who could benefit from transplant. And the performance failures of OPOs — explored in Post III — mean that potential donors whose families are willing are not always approached or are approached ineffectively.
The 30 daily deaths are not one thing. They are many things, each of which has a structural explanation and a policy address. None of them are random. They are the predictable output of an architecture — an architecture that a private nonprofit maintained, defended, and governed without competitive challenge for 37 years.
The waitlist is the most visible output of the organ transplant system's architecture, and it is the most politically durable insulation layer. The existence of a list implies a system — that the scarcity is being managed, that the allocation is ordered, that the process is fair. The list makes the deaths feel managed rather than produced. But the list is not the system. The list is the system's output. The deaths are not the cost of scarcity. They are partly the cost of the architecture — and that distinction is precisely what 37 years of single-contractor governance made difficult to name.
Next · Post III · The Regional Monopoly — 57 OPO territories, no competition, no decertification, no consequence. The procurement gap mapped.
No comments:
Post a Comment